Renaissance Technologies LLC raised its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 28.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 470,967 shares of the biopharmaceutical company’s stock after acquiring an additional 105,000 shares during the period. Renaissance Technologies LLC owned approximately 0.45% of Cytokinetics worth $25,517,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp grew its position in Cytokinetics by 642.3% during the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 456 shares during the period. EntryPoint Capital LLC purchased a new stake in Cytokinetics during the first quarter valued at about $74,000. Bessemer Group Inc. grew its position in Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 1,255 shares during the period. nVerses Capital LLC purchased a new stake in Cytokinetics during the second quarter valued at about $190,000. Finally, Kennedy Capital Management LLC purchased a new stake in Cytokinetics during the first quarter valued at about $224,000.
Insider Activity
In other news, Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $59.84, for a total transaction of $299,200.00. Following the completion of the transaction, the director now directly owns 20,600 shares of the company’s stock, valued at $1,232,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Fady Ibraham Malik sold 7,300 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $53.72, for a total value of $392,156.00. Following the completion of the transaction, the executive vice president now directly owns 133,004 shares of the company’s stock, valued at approximately $7,144,974.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director B Lynne Parshall sold 5,000 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $59.84, for a total value of $299,200.00. Following the completion of the transaction, the director now directly owns 20,600 shares of the company’s stock, valued at $1,232,704. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,837 shares of company stock valued at $6,018,383. 3.40% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on CYTK
Cytokinetics Stock Down 0.6 %
NASDAQ:CYTK opened at $55.60 on Friday. The firm has a market capitalization of $5.83 billion, a PE ratio of -10.30 and a beta of 0.77. The stock has a 50 day moving average of $56.28 and a 200-day moving average of $59.41. Cytokinetics, Incorporated has a 52 week low of $25.98 and a 52 week high of $110.25. The company has a current ratio of 10.39, a quick ratio of 10.39 and a debt-to-equity ratio of 5.93.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.25). The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $7.61 million. The company’s revenue was down 71.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.34) earnings per share. Analysts predict that Cytokinetics, Incorporated will post -5.15 EPS for the current year.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Featured Articles
- Five stocks we like better than Cytokinetics
- What Does a Stock Split Mean?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Transportation Stocks Investing
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is the NASDAQ Stock Exchange?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report).
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.